title: Bio-nanocapsules displaying various immunoglobulins as an active targeting-based drug delivery system.
abstract: The bio-nanocapsule (BNC) is an approximately 30-nm particle comprising the hepatitis B virus (HBV) envelope L protein and a lipid bilayer. The L protein harbors the HBV-derived infection machinery; therefore, BNC can encapsulate payloads such as drugs, nucleic acids, and proteins and deliver them into human hepatocytes specifically in vitro and in vivo. To diversify the possible functions of BNC, we generated ZZ-BNC by replacing the domain indispensable for the human hepatotrophic property of BNC (N-terminal region of L protein) with the tandem form of the IgG Fc-binding Z domain of Staphylococcus aureus protein A. Thus, the ZZ-BNC is an active targeting-based drug delivery system (DDS) nanocarrier that depends on the specificity of the IgGs displayed. However, the Z domain limits the animal species and subtypes of IgGs that can be displayed on ZZ-BNC. In this study, we introduced into BNC an Ig κ light chain-binding B1 domain of Finegoldia magna protein L (protein-L B1 domain) and an Ig Fc-binding C2 domain of Streptococcus species protein G (protein-G C2 domain) to produce LG-BNC. The LL-BNC was constructed in a similar way using a tandem form of the protein-L B1 domain. Both LG-BNC and LL-BNC could display rat IgGs, mouse IgG1, human IgG3, and human IgM, all of which not binding to ZZ-BNC, and accumulate in target cells in an antibody specificity-dependent manner. Thus, these BNCs could display a broad spectrum of Igs, significantly improving the prospects for BNCs as active targeting-based DDS nanocarriers.
  
  
  CONCLUSIONS
  We previously reported that ZZ-BNC, bio-nanocapsule deploying the IgG-binding Z domain of protein A, could display cell-specific antibody in an oriented immobilization manner, and act as an active targeting-based DDS nanocarrier. Since the Z domain can only bind to limited types of Igs, we generated BNCs deploying other Ig-binding domains: LL-BNC harboring the tandem form of Ig-binding domain of protein L, and LG-BNC harboring the Ig binding domains of protein L and protein G sequentially. Both BNCs could display a broader spectrum of Igs than does the ZZ-BNC. When these BNCs displayed anti-CD11c IgG or anti-EGFR IgG, both of which cannot bind to Z domain, they could bind to and then enter their respective target cells.
authors.affiliation: The Institute of Scientific and Industrial Research, Osaka University, Ibaraki 567-0047, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Tatematsu
authors.affiliation: The Institute of Scientific and Industrial Research, Osaka University, Ibaraki 567-0047, Japan.
authors.forename: Masumi
authors.initials: M
authors.lastname: Iijima
authors.affiliation: The Institute of Scientific and Industrial Research, Osaka University, Ibaraki 567-0047, Japan.
authors.forename: Nobuo
authors.initials: N
authors.lastname: Yoshimoto
authors.affiliation: The Institute of Scientific and Industrial Research, Osaka University, Ibaraki 567-0047, Japan.
authors.forename: Tadashi
authors.initials: T
authors.lastname: Nakai
authors.affiliation: The Institute of Scientific and Industrial Research, Osaka University, Ibaraki 567-0047, Japan.
authors.forename: Toshihide
authors.initials: T
authors.lastname: Okajima
authors.affiliation: The Institute of Scientific and Industrial Research, Osaka University, Ibaraki 567-0047, Japan. Electronic address: skuroda@sanken.osaka-u.ac.jp.
authors.forename: Shun'ichi
authors.initials: S
authors.lastname: Kuroda
mesh_terms: D000818:Animals; D000906:Antibodies / Q000378:metabolism; D001672:Biocompatible Materials / Q000737:chemistry*; D016503:Drug Delivery Systems / Q000379:methods*; D004705:Endocytosis; D006026:Glycoside Hydrolases / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007136:Immunoglobulins / Q000378:metabolism*; D007700:Kinetics; D051379:Mice; D053769:Nanocapsules / Q000737:chemistry* / Q000648:ultrastructure; D000072417:Protein Domains; D051381:Rats; D012441:Saccharomyces cerevisiae / Q000378:metabolism
chemical_list: D000906:Antibodies; D001672:Biocompatible Materials; D007074:Immunoglobulin G; D007136:Immunoglobulins; D053769:Nanocapsules; D006026:Glycoside Hydrolases
keywords: Active targeting-based DDS; Antibody; Bio-nanocapsule; Protein G; Protein L